Phibro Animal Health

Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment consists of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

PAHC reports Q3 sales growth, addresses challenges and opportunities

PAHC's Q3 2023 earnings call highlighted strong sales growth in the Animal Health segment, while facing challenges in the Mineral Nutrition segment. The company reiterated its full-year guidance and discussed various opportunities for growth and expansion.

Phibro Animal Health reports Q2 growth, adjusts guidance for 2023

Phibro Animal Health (PAHC) showed overall growth in net sales and adjusted EBITDA despite challenges in certain regions and segments.
The company remains focused on its full-year guidance but adjusted GAAP expectations due to environmental factors.
Strategic investments and market opportunities present avenues for future growth and performance improvement.

Phibro Animal Health reports strong Q3 sales growth and margin improvement

Phibro Animal Health Corporation demonstrated robust sales growth and margin improvement in the Animal Health segment, while facing challenges related to negative free cash flow. Despite this, the company remains optimistic about meeting its full-year guidance and sees opportunities for growth through market expansion and operational enhancements.

Phibro Animal Health reports strong FY 2023 performance and projects continued growth in Animal Health segment

Phibro Animal Health delivered solid financial performance in FY 2023, with a strong outlook for FY 2024 driven by growth in the Animal Health segment.
Strategic investments in vaccines and companion animals position the company for continued expansion and margin maintenance amidst challenges.
Efforts to enhance operational efficiency and cash flow generation underscore a commitment to sustainable growth and financial strength.
Anticipated top and bottom-line growth, along with market stability, signal a positive trajectory for Phibro Animal Health in the upcoming fiscal year.

Phibro Animal Health reports mixed Q1 results amid market challenges

Phibro Animal Health's Q1 2024 performance was marked by growth in the Animal Health segment but challenges in other segments.
Efforts to manage working capital effectively and maintain a stable financial position are key strengths.
However, declines in adjusted EBITDA, revenue, and margins present hurdles that require strategic solutions.
Opportunities for growth lie in addressing challenges across segments and exploring innovative market strategies.

Phibro Animal Health reports Q2 growth, affirms guidance amid challenges

Phibro Animal Health's Q2 2024 performance reflects solid growth in net sales driven by the Animal Health segment, despite challenges in other segments.
The company's ability to manage operational challenges in Israel and maintain guidance reaffirm confidence in its strategic direction and resilience.
With positive demand trends and a new CFO onboard, Phibro Animal Health is poised to leverage opportunities for growth and operational excellence.

Phibro Animal Health reports robust Q3 performance and strategic acquisitions

Phibro Animal Health (PAHC) delivered a strong Q3 performance with notable growth in total company and Animal Health sales, supported by positive financial metrics and strategic acquisitions.
While facing integration challenges and competitive pressures, the company's strengths in market performance, financial health, and strategic guidance position it well for future growth.
Opportunities in product expansion, market diversification, and innovation present avenues for sustained growth and market leadership in the animal health industry.

Phibro Animal Health posts strong Q4 results, eyes Zoetis acquisition

Phibro Animal Health (PAHC) delivered robust financial results in Q4 2024, driven by growth in key segments and operational improvements.
The pending Zoetis MFA acquisition and successful refinancing demonstrate Phibro's strategic focus on expansion and financial strength.
While challenges in integration and regulatory approvals exist, Phibro is well-positioned to capitalize on opportunities for market expansion and sustained growth.
Investors can look forward to Phibro's continued performance and value creation as it navigates industry dynamics and executes on its strategic initiatives.

Phibro Animal Health reports stellar Q1 results and eyes growth

Phibro Animal Health delivered impressive Q1 2025 results, showcasing robust financial growth and strategic acquisitions.
While facing challenges such as margin concerns and project discontinuations, the company remains optimistic about its future prospects.
By capitalizing on opportunities in the acquired portfolio and focusing on operational excellence, Phibro aims to sustain its growth trajectory and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 7, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 8, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (8.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock?

Why Is Phibro (PAHC) Up 13.6% Since Last Earnings Report?

Phibro Animal Health Corporation is expected to experience net sales growth and net income growth in the coming years. The company has a healthy balance sheet with little debt, which positions it well for successful expansion and innovation in its products. There are risks from changing regulations and competition, but overall, Phibro Animal appears undervalued.

Phibro Animal Health: Vaccine App And Analysts' Expectations Imply Undervaluation

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q1 2024 Earnings Conference Call November 9, 2023 9:00 AM ET Company Participants Daniel M. Bendheim - EVP, Corporate Strategy Jack C.

Phibro Animal Health Corporation (PAHC) Q1 2024 Earnings Call Transcript

Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.

Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down

While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Phibro (PAHC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

TEANECK, N.J.--(BUSINESS WIRE)--(NASDAQ: PAHC) The Food and Drug Administration (FDA), through its Center for Veterinary Medicine (CVM), has taken two actions regarding Mecadox® (carbadox), a drug marketed by Phibro Animal Health Corporation. In the first action, FDA has provided notice of a Federal Register publication issuing a final order to revoke the approved method for detecting residues of carbadox. FDA has also provided notice of a second Federal Register publication proposing to withdr.

Phibro Animal Health Corporation Reiterates Safety of Mecadox® and Intent to Defend its Use for Customers

Why Is Phibro (PAHC) Down 10.9% Since Last Earnings Report?

The COVID-19 pandemic has adversely affected the international economic conditions and financial markets, leading to an economic downturn in many countries, in which Phibro (PAHC) operates.

Phibro (PAHC) Sales Impacted by Macro Concerns, FX Headwind

The company's CFO resigned to take the CFO job at recycler TerraCycle. Yearly net income was down 34%.

Why Shares of Phibro Animal Health Are Dropping This Week

Robust performance across the Animal Health segment is encouraging for Phirbo (PAHC).

Phibro (PAHC) Q4 Earnings Miss Estimates, Gross Margin Falls

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q4 2023 Results Conference Call August 31, 2023 9:00 AM ET Company Participants Damian Finio - Chief Financial Officer Jack Bendheim - Chairman, President and Chief Executive Officer Donny Bendheim - Director and Executive Vice President, Corporate Strategy Conference Call Participants Brian Wright - ROTH MKM Michael Ryskin - Bank of America Operator Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your operator today.

Phibro Animal Health Corporation (PAHC) Q4 2023 Earnings Call Transcript

Phibro (PAHC) input costs continue to be high as a result of sustained inflation.

Phibro's (PAHC) Sales Hurt by Rising Costs, FX Headwind

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2023 financial results on Wednesday, August 30, 2023, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 31, 2023, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting http://investors.pahc.com. The discussion will also be availabl.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2023 Results

Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.

Here's Why Investors Should Retain Phibro (PAHC) for Now

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) is a global leader in animal health and mineral nutrition. We partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals. We provide solutions to help them maintain and enhance the health of their animals. We are proud to share our second Environmental, Social and Governance (ESG) Report (the “Report”). The Report highlights certain key performance indica.

Phibro Issues Second Environmental, Social and Governance Report

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q3 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Damian Finio - Chief Financial Officer Jack Bendheim - Chairman, President and CEO Daniel Bendheim - Director and Executive Vice President, Corporate Strategy Conference Call Participants Wolf Chanoff - BofA Securities Brian Wright - ROTH MKM Partners Operator Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today.

Phibro Animal Health Corporation (PAHC) Q3 2023 Earnings Call Transcript

Higher domestic demand and higher average selling prices for dairy products and growth in the companion animal product drive Phibro's (PAHC) Q3 revenues.

Phibro (PAHC) Q3 Earnings Miss Estimates, Gross Margin Up

Phibro Animal Health (PAHC) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.33 per share a year ago.

Phibro Animal Health (PAHC) Q3 Earnings Lag Estimates

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter and year-to-date ended March 31, 2023. Highlights for the three months ended March 31, 2023 (compared to the three months ended March 31, 2022) Net sales of $245.7 million, an increase of $6.1 million, or 3% Net income of $10.0 million, a decrease of $7.6 million, or 43% Diluted EPS of $0.25, a decrease of $0.19, or 43% Adjusted EBIT.

Phibro Animal Health Corporation Reports Third Quarter and Year-to-Date Results

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 3, 2023, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 4, 2023, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Financial Results

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America Securities 2023 Health Care Conference. Chief Financial Officer Damian Finio will address financial analysts and investors on Tuesday, May 9, 2023, at 4:20 PM PDT. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com.

Phibro Animal Health Corporation to Participate in Bank of America Securities 2023 Health Care Conference.

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq:PAHC) announced today it will participate in the Bank of America 2023 Virtual Animal Health Summit. Chief Financial Officer Damian Finio and Executive Vice President, Corporate Strategy Daniel Bendheim will address financial analysts and investors on Thursday, March 2, 2023, at 10:50 AM ET. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.

Phibro Animal Health Corporation to Participate in Bank of America 2023 Animal Health Summit

Growing uptake of MFAs, dairy products and vaccines contributed to Phibro's (PAHC) Q2 revenues.

Phibro (PAHC) Q2 Earnings Top Estimates, Gross Margin Up

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q2 2023 Earnings Conference Call February 9, 2023 9:00 AM ET Company Participants Damian Finio - Chief Financial Officer Jack Bendheim - Chairman, President and CEO Daniel Bendheim - Director and Executive Vice President, Corporate Strategy Conference Call Participants Brian Wright - ROTH MKM Operator Good morning. My name is Jeannie, and I will be your conference operator today.

News for Phibro Animal Health Stock (PAHC)